BACKGROUND

The Philippines is hyperendemic for hepatitis B infection. Vaccination is crucial for protection. Local data on the antibody response after completion of the primary vaccination series is limited.

This study aimed to measure the anti-HBs levels among college students who completed primary hepatitis B vaccination series, compare seropositivity across stratified groups and correlate anti-HBs levels with the time elapsed since the last vaccine dose.

This cross-sectional study included 111 college students in health-related courses with immunization record showing the complete primary Hepatitis B vaccination series. Participants were stratified based on the following vaccination schedules: 0-1-6-month group; 0-1-2-month group; and booster group. Anti-HBs titers were determined.

Statistical analyses included One-way ANOVA, Kruskal-Wallis test, Fisher’s Exact test and Shapiro-Wilk normality test. Kaplan-Meier Survival Estimate assessed the probability of anti-HBs seropositivity over time. Data were analyzed using STATA 13.1.

The baseline characteristics of the study population were homogenous. The median anti-HBs titer several years after primary vaccination was low at 2.9 mIU/mL. Participants in the booster group had the highest seropositivity rate (57.14%) with a median titer of 30.16 mIU/mL. There was an inverse relationship between anti-HBs titer and elapsed time since the last vaccine dose. Kaplan-Meier Survival Estimate showed that the seropositivity decreases to 90.56% after 15.8 years, 51.3% after 17.5 years, and 2.97% at 18 years.

This study revealed low anti-HBs titers among students who previously completed primary vaccination series, with no significant difference between two schedules. Booster doses resulted in the highest seropositivity. Over-all, seropositivity declines over time.

A model of immunization of viral hepatitis B with low cost and high efficacy was established in HoChiMinh city with a procedure of two episodes of vaccination. The cost effectiveness was analysed. The non-screening method was recommended for children of 10-14 years old with a procedure of two episodes of vaccination. If possible, HBsAg test must be done for prevention and treatment rather than for economic aims
Hepatitis ; Hepatitis B ; Child

The economic effectiveness of two model of B hepatitis immunization for the group of 20-29 years old living in Ho Chi Minh city was analyzed in the year 2003. The related parameters were: HBV incidence, the protecting effect the vaccin, the complicance of immunization schedule, the cost of vaccin and of laboratory assay, the travelling cost, the income loss, service fee devoted for health staff. Result showed that the model of supplies of vaccin in living and working fields for users had had absolute predominance with 1 diminutrition of 7.345.000 VND for 100 cases of preventive vaccination
hepatitis B ; Hepatitis ; Diseases

The KAP survey on liver disease, hepatitis B and EPI was conducted in Quang Xuong and Ngoc Lac (Thanh Hoa) in October 2000. The results: there were more than 50% of interviewees giving completely correct answers on liver disease. Monthly visits of EPI staffs increased three times in Ngoc Lac to compare with this of 3 years ago. Radio/TV and loudspeakers are still the main ways to inform EPI activities. Knowledge of mothers on vaccination has been improved. The rate of having birth at CHS has increased in Ngoc Lac (from 6.2% to 34.2%)
Hepatitis, Chronic ; hepatitis B

485 patients were admitted in Institute of Clinical Medicine and Tropical diseases from 12/1995 to 1/1999, from which 72.4% were male and 27.6% were female. Most of the patients under 40 years old (77.3%). The rate of infecting viral hepatitis B is highest: 55.1%, HAV: 12.8%, HEV: 4.3%, HCV: 2.9% and rate of patients with multiple hepatitis virus infection is 18.1%. Besides 6.8% patients don't have the serum marker in the serum.
Hepatitis ; Hepatitis B

No abstract available.
Hepatitis B* ; Hepatitis*

No abstract available.
Hepatitis B* ; Hepatitis* ; Vaccination*

No abstract available.
Hepatitis B* ; Hepatitis*

No abstract available.
Hepatitis B* ; Hepatitis* ; Prevalence*

No abstract available.
Hepatitis B* ; Hepatitis*